Terms: = Leukemia AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
70 results:
1. Chronic Lymphocytic leukemia IGHV Somatic Hypermutation Detection by Targeted Capture Next-Generation Sequencing.
Grants JM; May C; Bridgers J; Huang S; Gillis S; Meissner B; Boyle M; Ben-Neriah S; Hung S; Duns G; Hilton L; Gerrie AS; Marra M; Kridel R; Sabatini PJB; Steidl C; Scott DW; Karsan A
Clin Chem; 2024 Jan; 70(1):273-284. PubMed ID: 38175592
[TBL] [Abstract] [Full Text] [Related]
2. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic leukemia Relapsing after First-Line treatment with Fixed-Duration Ibrutinib plus Venetoclax.
Jain N; Croner LJ; Allan JN; Siddiqi T; Tedeschi A; Badoux XC; Eckert K; Cheung LWK; Mukherjee A; Dean JP; Szafer-Glusman E; Seymour JF
Clin Cancer Res; 2024 Feb; 30(3):498-505. PubMed ID: 37955424
[TBL] [Abstract] [Full Text] [Related]
3. Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.
Molica S; Tam C; Allsup D; Polliack A
Hematol Oncol; 2024 Jan; 42(1):e3238. PubMed ID: 37937506
[TBL] [Abstract] [Full Text] [Related]
4. xpo1 is a new target of homoharringtonine (HHT): Making NPMc
Xue J; Chu P; Gao W; Wang F; Gao Y; Liu S; Kang Z; Yan J; Wang H
Biochem Biophys Res Commun; 2023 Oct; 675():155-161. PubMed ID: 37473530
[TBL] [Abstract] [Full Text] [Related]
5. Azacitidine Is Synergistically Lethal with xpo1 Inhibitor Selinexor in Acute Myeloid leukemia by Targeting xpo1/eIF4E/c-MYC Signaling.
Long H; Hou Y; Li J; Song C; Ge Z
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047788
[TBL] [Abstract] [Full Text] [Related]
6. Covalent targeting the LAS1-NOL9 axis for selective treatment in NPM1 mutant acute myeloid leukemia.
Han Y; Hu A; Qu Y; Xu Q; Wang H; Feng Y; Hu Y; He L; Wu H; Wang X
Pharmacol Res; 2023 Mar; 189():106700. PubMed ID: 36796466
[TBL] [Abstract] [Full Text] [Related]
7. Synthetic lethal targeting of TET2-mutant haematopoietic stem and progenitor cells by xpo1 inhibitors.
Jing CB; Prutsch N; He S; Zimmerman MW; Landesman Y; Look AT
Br J Haematol; 2023 May; 201(3):489-501. PubMed ID: 36746437
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic value and therapeutic targeting of xpo1 in chronic lymphocytic leukemia.
Xu Z; Pan B; Miao Y; Li Y; Qin S; Liang J; Kong Y; Zhang X; Tang J; Xia Y; Zhu H; Wang L; Li J; Wu J; Xu W
Clin Exp Med; 2023 Oct; 23(6):2651-2662. PubMed ID: 36738306
[TBL] [Abstract] [Full Text] [Related]
9. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of xpo1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract] [Full Text] [Related]
10. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L; Thorvaldsdottir B; Sutton LA; Karakatsoulis G; Meggendorfer M; Parker H; Nadeu F; Brieghel C; Laidou S; Moia R; Rossi D; Catherwood M; Kotaskova J; Delgado J; Rodríguez-Vicente AE; Benito R; Rigolin GM; Bonfiglio S; Scarfo L; Mattsson M; Davis Z; Gogia A; Rani L; Baliakas P; Foroughi-Asl H; Jylhä C; Skaftason A; Rapado I; Miras F; Martinez-Lopez J; de la Serna J; Rivas JMH; Thornton P; Larráyoz MJ; Calasanz MJ; Fésüs V; Mátrai Z; Bödör C; Smedby KE; Espinet B; Puiggros A; Gupta R; Bullinger L; Bosch F; Tazón-Vega B; Baran-Marszak F; Oscier D; Nguyen-Khac F; Zenz T; Terol MJ; Cuneo A; Hernández-Sánchez M; Pospisilova S; Mills K; Gaidano G; Niemann CU; Campo E; Strefford JC; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2023 Feb; 37(2):339-347. PubMed ID: 36566271
[TBL] [Abstract] [Full Text] [Related]
11. Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome.
Janssen JJWM; Löwenberg B; Manz M; Biemond BJ; Westerweel PE; Klein SK; Fehr M; Sinnige HAM; Efthymiou A; Legdeur MCJC; Pabst T; Gregor M; van der Poel MWM; Deeren D; Tick LW; Jongen-Lavrencic M; van Obbergh F; Boersma RS; de Weerdt O; Chalandon Y; Heim D; Spertini O; van Sluis G; Graux C; Stüssi G; van Norden Y; Ossenkoppele GJ
Leukemia; 2022 Sep; 36(9):2189-2195. PubMed ID: 35869267
[TBL] [Abstract] [Full Text] [Related]
12. Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence.
Misund K; Hofste Op Bruinink D; Coward E; Hoogenboezem RM; Rustad EH; Sanders MA; Rye M; Sponaas AM; van der Holt B; Zweegman S; Hovig E; Meza-Zepeda LA; Sundan A; Myklebost O; Sonneveld P; Waage A
Leukemia; 2022 Jul; 36(7):1887-1897. PubMed ID: 35643867
[TBL] [Abstract] [Full Text] [Related]
13. Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.
Ishikawa C; Mori N
Invest New Drugs; 2022 Aug; 40(4):718-727. PubMed ID: 35477814
[TBL] [Abstract] [Full Text] [Related]
14. Venetoclax enhances DNA damage induced by xpo1 inhibitors: A novel mechanism underlying the synergistic antileukaemic effect in acute myeloid leukaemia.
Yu H; Wu S; Liu S; Li X; Gai Y; Lin H; Wang Y; Edwards H; Ge Y; Wang G
J Cell Mol Med; 2022 May; 26(9):2646-2657. PubMed ID: 35355406
[TBL] [Abstract] [Full Text] [Related]
15. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.
Balasubramanian SK; Azmi AS; Maciejewski J
Leukemia; 2022 Mar; 36(3):601-612. PubMed ID: 35091658
[TBL] [Abstract] [Full Text] [Related]
16. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.
Burger JA; Robak T; Demirkan F; Bairey O; Moreno C; Simpson D; Munir T; Stevens DA; Dai S; Cheung LWK; Kwei K; Lal I; Hsu E; Kipps TJ; Tedeschi A
Leuk Lymphoma; 2022 Jun; 63(6):1375-1386. PubMed ID: 35014928
[TBL] [Abstract] [Full Text] [Related]
17. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract] [Full Text] [Related]
18. A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Martínez Sánchez MP; Megías-Vericat JE; Rodríguez-Veiga R; Vives S; Bergua JM; Torrent A; Suárez-Varela S; Boluda B; Martínez-López J; Cano-Ferri I; Acuña-Cruz E; Torres-Miñana L; Martín-Herreros B; Serrano A; Sempere A; Barragán E; Sargas C; Sanz M; Martínez-Cuadrón D; Montesinos P;
Ann Hematol; 2021 Jun; 100(6):1497-1508. PubMed ID: 33914097
[TBL] [Abstract] [Full Text] [Related]
19. The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and xpo1 genes: a report from the LRF CLL4 trial.
Else M; Blakemore SJ; Strefford JC; Catovsky D
Leukemia; 2021 Sep; 35(9):2563-2569. PubMed ID: 33580200
[TBL] [Abstract] [Full Text] [Related]
20. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, xpo1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract] [Full Text] [Related]
[Next]
